Significant asset restructuring changes, jinfa labi maternity & baby articles plans to reduce the acquisition of symbol equity to 51% | Quick read announcement.

① Jinfa Labi has terminated the major assets restructuring and changed to acquiring 51% equity of Zhuhai Hanfei and Zhongshan Hanfei, which does not constitute a major assets restructuring. ② Jinfa Labi has reported net income losses for two consecutive years, with revenue of 0.139 billion yuan in the first three quarters, a year-on-year decline of 7.63%, and a net income of -9.9525 million yuan attributable to shareholders.

cls.cnNov 17 21:46

Abnormal trading investigation! The big bull stock special treat Jingfeng has been suspended for the first time, with an increase of over 752% in more than four months | Quick read of the announcement.

①*ST Jingfeng suspended trading for the first time this year due to abnormal fluctuations; ② The cumulative deviation of the closing price for two consecutive trading days reached 15.39%; ③ The stock price has increased by 752.78% in the past four months; ④ There is still uncertainty about the highly anticipated pre-restructuring matters.

cls.cnNov 17 19:31

Refrigerant leader zhejiang juhua: Some products in Q4 have stabilized after the decline, opportunities outweigh challenges next year. | Directly target the earnings conference

①It is expected that refrigerant prices will rebound across the board in Q4, while non-refrigerants will stabilize; ②Optimistically view next year's performance prospects, pointing out the coexistence of opportunities and challenges; ③Next year, the certainty of refrigerant price increases is strong, and the competitive landscape has improved somewhat; ④ Non-refrigerants are still in surplus, but the risk of a major drop over the past two years has been released.

cls.cnNov 12 18:13

Investors are paying attention to the progress of FT606. shandong lukang pharmaceutical did not directly respond to the production time | Live coverage of the earnings conference.

①The progress of the company's new synthetic biotechnology material product FT606 has attracted much attention. ②The pharmaceutical industry was in the traditional off-season in the third quarter, leading to a decline in the company's Q3 earnings. ③During the earnings conference, a questioner who claimed to be an investor expressed dissatisfaction with the lack of interaction.

cls.cnNov 8 21:51

SSE successively inquired about listed companies' 'cross-border mergers and acquisitions' with a focus on valuation and performance bets.

Dalian bio-chem's cross-border increased investment in Xinhui Lian attracted the attention of the Shanghai Stock Exchange. This time, Xinhui Lian's pre-investment valuation was 0.8 billion yuan, priced at 0.7 billion yuan, but Dalian bio-chem's investment in Xinhui Lian only involves part of Xinhui Lian's assets, not including the development of "wafer bonding machine" business. Dongguan Huali Industries and Jiangxi Lianchuang Opto-Electronic Science&Technology have recently been questioned by the Shanghai Stock Exchange, all involving high premium acquisitions, performance guarantees, and so on.

cls.cnOct 30 20:55

Below expectations? Refrigerant prices are steadily rising, zhejiang juhua's Q3 net profit declined compared to the previous quarter|Interpretations

1. The company's Q3 net profit declined compared to the previous quarter, and investor comments were below expectations; 2. It is becoming increasingly difficult to meet the full-year performance expectations set by the brokerage; 3. The structural contradictions of the product are prominent, with some products continuously dragging down performance; 4. The off-season for refrigerants in Q3 also had an impact, but demand in Q4 has not shown a clear increase.

cls.cnOct 24 21:12